TY - JOUR
T1 - Ivabradine for Uncontrolled Sinus Tachycardia in Thyrotoxic Cardiomyopathy-Case Report
AU - Frenkel, Amit
AU - Bichovsky, Yoav
AU - Arotsker, Natan
AU - Besser, Limor
AU - Joshua, Ben Zion
AU - Fraenkel, Merav
AU - Zahger, Doron
AU - Klein, Moti
N1 - Publisher Copyright:
© 2023 Bentham Science Publishers.
PY - 2023/1/1
Y1 - 2023/1/1
N2 - Background: Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents. However, when thyrotoxicosis is not controlled, heart rate may be difficult to control even with maximal doses of propranolol. This presentation alerts physicians to the possibility of using ivabradine, a selective inhibitor of the sinoatrial pacemaker, for the control of heart rate. Case Presentation: We present a 37-year-old woman with thyrotoxicosis and congestive heart failure whose heart rate was not controlled with a maximal dose of beta blockers during a thyroid storm. The addition of ivabradine, a selective inhibitor of the sinoatrial pacemaker, controlled her heart rate within 48 hours. Conclusion: Ivabradine should be considered in patients with thyrotoxicosis, including those with heart failure, in whom beta blockers are insufficient to control heart rate.
AB - Background: Beta-blockers, mainly propranalol, are usually administered to control heart rate in patients with thyrotoxicosis, especially when congestive heart failure presents. However, when thyrotoxicosis is not controlled, heart rate may be difficult to control even with maximal doses of propranolol. This presentation alerts physicians to the possibility of using ivabradine, a selective inhibitor of the sinoatrial pacemaker, for the control of heart rate. Case Presentation: We present a 37-year-old woman with thyrotoxicosis and congestive heart failure whose heart rate was not controlled with a maximal dose of beta blockers during a thyroid storm. The addition of ivabradine, a selective inhibitor of the sinoatrial pacemaker, controlled her heart rate within 48 hours. Conclusion: Ivabradine should be considered in patients with thyrotoxicosis, including those with heart failure, in whom beta blockers are insufficient to control heart rate.
KW - Thyrotoxicosis
KW - congestive heart failure
KW - heart rate
KW - ivabradine
KW - sinus tachycardia
KW - thyrotoxic cardiomyopathy
UR - http://www.scopus.com/inward/record.url?scp=85159762148&partnerID=8YFLogxK
U2 - 10.2174/1871530323666221214141205
DO - 10.2174/1871530323666221214141205
M3 - Article
C2 - 36518043
AN - SCOPUS:85159762148
SN - 1871-5303
VL - 23
SP - 992
EP - 995
JO - Endocrine, Metabolic and Immune Disorders - Drug Targets
JF - Endocrine, Metabolic and Immune Disorders - Drug Targets
IS - 7
ER -